
SNTI Stock Forecast & Price Target
SNTI Analyst Ratings
Bulls say
Senti Biosciences Inc., a clinical-stage biotechnology firm, is advancing its innovative gene circuit platform technologies through multiple product candidates, notably SENTI-202 and SENTI-301A, which target oncology indications with promising preclinical outcomes. The company's focus on allogeneic CAR-NK cells suggests a potentially safer profile compared to traditional CAR-T therapies, which is supported by statistically significant enhancements in anti-tumor activity and patient survival in preclinical models. Additionally, the designation of Orphan Drug Designation (ODD) for SENTI-202 indicates favorable regulatory support, potentially enabling Senti to secure strategic partnerships and investor interest while establishing a robust clinical supply ahead of critical data releases scheduled for 4Q25.
Bears say
Senti Biosciences Inc. faces significant challenges that contribute to a negative outlook on its stock. Key concerns include the expectation of a decline in complete response (cCR) rates from the initial 57% due to the aggressive nature of acute myeloid leukemia (AML), which raises doubts about clinical efficacy and potential revisions to financial projections. Furthermore, the company has notable risks related to safety signal emergence, competition, regulatory approvals, cash runway beyond 2025, and the need for substantial additional financing, all of which may hinder its growth and performance compared to competitors within the allogeneic cell therapy market.
This aggregate rating is based on analysts' research of Senti Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
SNTI Analyst Forecast & Price Prediction
Start investing in SNTI
Order type
Buy in
Order amount
Est. shares
0 shares